A randomized study of extended treatment with peginterferon α-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C

American Journal of Gastroenterology

Volumn 104, Issue 1, 2009, Pages 70-75

  Ide, Tatsuya ^a   Hino, Teruko ^a   Ogata, Kei ^a   Miyajima, Ichiro ^a   Kuwahara, Reiichiro ^a   Kuhara, Koichiro ^a   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA2B INTERFERON; ANTIVIRUS AGENT; PEGINTERFERON ALFA-2B; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GENOTYPE; GINGIVITIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; RETINOPATHY; THYROIDITIS; TREATMENT DURATION; VIRUS LOAD; DRUG ADMINISTRATION; DRUG COMBINATION; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; YOUNG ADULT;

EID: 60749103034     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2008.60     Document Type: Article

References (21)

1. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002. Hepatology 2002;36:S3-20.
2. Alberti A, Benvegmi L. Management of hepatitis C. J Hepatol 2003;38:S104-18.
3. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
4. Hadziyannis S, Sette H Jr, Morgan TR et al. Peginterferon-alfa-2a plus ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;40:346-55.
5. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-9.
6. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004;140:370-81.
7. Berg T, Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 vs. 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-97.
8. Sanchez-Tapias J, Diago M, Escartín P et al. Peginterferon-alfa2a plus ribavirin for 48 vs. 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006;131:451-60.
9. Mangia A, Minerva N, Bacca D et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008;47:43-50.
10. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007;46:1688-94.
11. Brouwer JT, Nevens F, Bekkering FC, et al., for the Benelux Study Group. On treatment of chronic hepatitis C. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. J Hepatol 2004;40:689-95.
12. Buti M, Valdez A, Sanchez-Avila F et al. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology 2003;37: 1226-7.
13. Poynard T, McHutchison J, Goodman Z, et al., for the ALGOVIRC Project Group. Is an "A la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment of patients with chronic hepatitis C? Hepatology 2000;31:211-28.
14. Ferenci P, Fried MW, Shiftman ML et al. Predicting sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005;43:425-33.
15. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004;189:964-70.
16. Okamoto H, Sugiyama Y, Okada S et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73: 673-9.
17. Simmonds P, Holmes EC, Cha TA et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74:2391-9.
18. Desmet VJ, Gerber M, Hoofnagle JH et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
19. Marcellin P, Heathcote EJ, Craxì A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the "accordion" regimen? J Hepatol 2007;47:580-7.
20. Jensen DM, Morgan TR, Marcellin P et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-60.
21. Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.